Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Site News
Market: Market:

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201 Globe Newswire - Tue Jan 18, 8:30AM CST

Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection...

ATOS : 1.2600 (-3.82%)
Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden Globe Newswire - Wed Dec 22, 2021

SEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop...

ATOS : 1.2600 (-3.82%)
Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration Globe Newswire - Mon Dec 6, 2021

Input Received on Pathway for Proprietary Z-Endoxifen to Treat Breast Cancer in Neoadjuvant Setting...

ATOS : 1.2600 (-3.82%)
Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 “A Town Hall Q&A Event With Atossa Therapeutics Management Team” Globe Newswire - Wed Nov 24, 2021

Atossa’s CEO & Founder, Dr. Steven Quay, M.D., Ph.D. ...

ATOS : 1.2600 (-3.82%)
Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update Globe Newswire - Mon Nov 15, 2021

SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop...

ATOS : 1.2600 (-3.82%)
Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month Globe Newswire - Thu Oct 21, 2021

Global Pandemic Caused a Significant Drop In Mammograms as Clinics Remained Closed...

ATOS : 1.2600 (-3.82%)
Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia Globe NewsWire - Thu Sep 30, 2021

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE

ATOS : 1.2600 (-3.82%)
Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote Globe NewsWire - Tue Sep 7, 2021

Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor

ATOS : 1.2600 (-3.82%)
Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden Globe NewsWire - Thu Sep 2, 2021

SEATTLE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant...

ATOS : 1.2600 (-3.82%)
Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting Globe NewsWire - Fri Aug 13, 2021

SEATTLE, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious...

ATOS : 1.2600 (-3.82%)

Barchart Exclusives

Hedging Inflation: Currencies, Kings, and Weather Derivatives Barchart - Fri Jan 21, 11:32AM CST
One of the most popular topics these days is US inflation, and with that attention turns to how to hedge against it. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' : 'CST' ]] CDT
Reserve Your Spot